Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 2
1966 1
1967 1
1970 1
1972 1
1973 2
1974 1
1985 1
1988 1
1989 1
1992 1
1993 1
1995 1
1996 1
1998 3
1999 2
2000 2
2001 4
2002 4
2003 5
2004 4
2005 7
2006 4
2007 7
2008 2
2009 3
2010 6
2011 3
2012 13
2013 19
2014 11
2015 4
2016 10
2017 13
2018 21
2019 14
2020 16
2021 29
2022 22
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: cho ky. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Clinical Trial.
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Among authors: cho ky. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
Intraspinal ganglion cyst.
Mun JH, Lee RS, Lim BC, Lim JS, Cho KY. Mun JH, et al. Among authors: cho ky. Chonnam Med J. 2012 Dec;48(3):183-4. doi: 10.4068/cmj.2012.48.3.183. Epub 2012 Dec 21. Chonnam Med J. 2012. PMID: 23323226 Free PMC article.
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H, Takahashi A, Nakamura A, Kurihara H, Takeuchi J, Nagai S, Taneda S, Miya A, Kameda H, Cho KY, Miyoshi H, Atsumi T. Nomoto H, et al. Among authors: cho ky. BMJ Open Diabetes Res Care. 2022 Nov;10(6):e002988. doi: 10.1136/bmjdrc-2022-002988. BMJ Open Diabetes Res Care. 2022. PMID: 36379585 Free PMC article.
228 results